MedPath

Repeat prostate evaluation and therapy pilot study in patients undergoing high dose rate brachytherapy for prostate cancer

Not Applicable
Completed
Conditions
Prostate Cancer
Cancer - Prostate
Registration Number
ACTRN12610001076066
Lead Sponsor
Peter MacCallum Cancer Centre
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Male
Target Recruitment
13
Inclusion Criteria

Patients undergoing high dose rate brachytherapy for prostate cancer

Exclusion Criteria

previous transurethral resection of prostate (TURP), anticoagulation, previous sepsis from prostate biopsy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
nacceptable Toxicity Rate - a composite measure of infection (requiring >5 days of antibiotics), patient tolerance (refusal of subsequent biopsy) and grade 3 toxicity (using NCI CTC criteria)[6 weeks following intervention completion]
Secondary Outcome Measures
NameTimeMethod
presence of prostate tissue on each biopsy assessed using light microscopy[6 weeks following intervention completion]
© Copyright 2025. All Rights Reserved by MedPath